Premium
Proteomic analysis of a lymphoma‐derived cell line (DG75) following treatment with a demethylating drug: Modification of membrane‐associated proteins
Author(s) -
Poirier Florence,
JoubertCaron Raymonde,
Labas Valérie,
Caron Michel
Publication year - 2003
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200300374
Subject(s) - proteomics , chemistry , cell , membrane protein , cell culture , cell membrane , tandem mass spectrometry , membrane , mass spectrometry , biochemistry , biology , chromatography , genetics , gene
5’‐azacytidine (AZC) is a potent DNA demethylating agent used clinically for treatment of patients with malignant hemopathies. We have previously shown that AZC induces a halt in cell growth and a decrease of cell activity, without affecting cell viability. We have also shown using proteomics, that 35 polypeptides were differentially expressed in a cytoplasmic fraction. The aim of this study was to provide a more complete picture of modifications in AZC‐treated cells using cell membrane preparations. Therefore the protein pattern changes following AZC treatment of the cell line DG75 were studied on a detergent‐solubilized fraction obtained from these membranes. Results showed that 49 proteins were differentially expressed in the membrane fraction. Seven polypeptides were down‐regulated, while 42 were up‐regulated. The identity of most of these differentially expressed proteins was determined by mass spectrometry (liquid chromatography‐tandem mass spectrometry or matrix‐assisted laser desorption/ionization‐time of flight), and the identified proteins were grouped based on cellular function and participation in biochemical and signaling pathways.